"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Christina Farr, Luba Greenwood, Ash Zenooz
39 episodes
4 months ago
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
All content for "Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD is the property of Christina Farr, Luba Greenwood, Ash Zenooz and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
How dietary guidelines changed our rate of aging with Stephanie Venn-Watson
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
30 minutes
6 months ago
How dietary guidelines changed our rate of aging with Stephanie Venn-Watson
This week on Second Opinion, Christina Farr and Ash Zenooz interview Seraphina Therapeutics CEO Steph Venn-Watson, unpacking why men dominate the longevity space, the cellular secrets of aging, and C15:0’s potential to boost health.
—📰 Be notified early when Turpentine drops new publication: https://www.turpentine.co/exclusiveaccess —SPONSOR:🏋🏻♀️ Strengthen your cells from the inside-out with Fatty15, a pure C15:0 supplement proven to boost energy, improve sleep, and support metabolic, heart, and liver health – without the downsides of fish oil. Ready to restore your long-term health? Get 15% off your 90-day subscription Starter Kit at https://fatty15.com/secondopinion using code SECONDOPINION at checkout.
🏥 Thatch makes it easy to give your team great healthcare. Save ~$1620 per employee yearly while giving them customizable plans. Visit https://thatch.ai/HR for a demo and receive a $100 gift card.
—LINKS: The Longevity Nutrient: https://www.amazon.com/Longevity-Nutrient-Unexpected-Holds-Healthy/dp/1668063549 Subscribe to Second Opinion Newsletter: https://secondopinion.media/
—FOLLOW:https://www.linkedin.com/in/stephanievennwatson/https://www.linkedin.com/in/christinafarr/ https://www.linkedin.com/in/ashzenooz/
—HIGHLIGHTS FROM THE EPISODE:
Christina Farr, Ash Zenooz and Seraphina Therapeutics CEO Stephanie Venn-Watson explore women's perspectives on longevity versus the male-dominated "influencer" space in this field.
Stephanie explains that traditional "longevity" focused on living forever doesn't resonate with most women, who instead want quality years.
Stephanie reveals concerning data that people born after 1990 are showing aging-related diseases at younger ages than previous generations.
While studying Navy dolphins, Stephanie's team discovered that a molecule called C15:0 (pentadecanoic acid) was linked to healthier aging.
C15:0 is a saturated fat primarily found in dairy fat, which has been significantly reduced in American diets since 1977 dietary guidelines.
The 1977 congressional guidelines recommended decreasing saturated fat intake, leading to widespread adoption of low-fat dairy.
This dietary shift doubled down in the 1990s when pediatricians began recommending switching children from whole milk to low-fat milk at age two.
People born since the 1990s have grown up in what Stephanie calls a "C15:0 deficient world."
The good news is that C15:0 supplementation can help reverse some of these conditions according to clinical trials.
C15:0 levels can also be increased through diet (especially grass-fed dairy), exercise, and consuming fiber.
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
